Read by QxMD icon Read

Asia-Pacific Journal of Clinical Oncology

Yoshimasa Saito, Tadashi Kumamoto, Miki Shiraiwa, Tomoko Sonoda, Ayumu Arakawa, Hironobu Hashimoto, Ikumi Tamai, Chitose Ogawa, Hiroyuki Terakado
AIM: Although hemorrhagic cystitis (HC) is a significant complication in young patients who undergo chemotherapy with cyclophosphamide (CPA), risk factors and supportive care to prevent HC are unclear. This study attempted to identify optimal supportive care to prevent CPA-induced HC. METHODS: Patients (< 30-year-old) with malignant solid tumors who had been treated with CPA-containing chemotherapy in inpatient treatment were eligible. Vigorous hydration to increase urine output and intravenous 2-mercaptethane sulfonate (mesna) were used for prophylaxis of CPA-induced HC...
July 10, 2018: Asia-Pacific Journal of Clinical Oncology
Takeshi Kotake, Hironaga Satake, Yoshihiro Okita, Yukimasa Hatachi, Mamiko Hamada, Masatomo Omiya, Hisateru Yasui, Toru Hashida, Satoshi Kaihara, Tetsuro Inokuma, Akihito Tsuji
BACKGROUND: Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown. AIM: To evaluate the prevalence and risk factors of HBV reactivation in patients with solid tumors with resolved HBV infection. METHODS: All 1088 patients with solid tumors were assessed for eligibility; 251 patients had resolved HBV infection (negative for HBs antigen and positive for anti-HBc antibody and/or positive for anti-HBs antibody), and HBV-DNA was assessed for 243 of these patients in whom we analyzed the prevalence of HBV reactivation...
July 8, 2018: Asia-Pacific Journal of Clinical Oncology
Cheng-Hao Chuang, Jui-Feng Hsu, Yu-Ting Shen, Chih-Jen Yang
An abscopal effect refers to distant tumor regression after localized irradiation. The mechanism is thought to be via local radiotherapy triggering the immune system which then attacks distant tumor sites. Only several cases of solid tumors with an abscopal effect have been reported in the past few decades, and whether an abscopal effect can cross the blood-brain barrier is still unknown. Herein, we present a female patient who was admitted due to unsteady gait and dyspnea. Chest X-ray (CXR) and chest CT showed a huge lung mass with left lung collapse and multiple liver masses...
July 8, 2018: Asia-Pacific Journal of Clinical Oncology
Yoshimi Ishii, Shin Fujisawa, Taiki Ando, Taisei Suzuki, Yasufumi Ishiyama, Kumiko Kishimoto, Yukako Hattori, Yuki Nakajima, Takuya Miyazaki, Hirotaka Takasaki, Kenji Matsumoto, Hideyuki Koharazawa, Jun Taguchi, Katsumichi Fujimaki, Rika Sakai, Hideaki Nakajima
AIM: Primary malignant lymphomas arising from the female genital tract are very rare, with an incidence rate of 0.5%. Because of its rarity, its clinical characteristics, prognosis and optimal treatment are still unclear. Here, we retrospectively evaluated female patients with uterine lymphoma. METHODS: Between January 2000 and October 2016, 4362 patients were newly diagnosed with malignant lymphoma by the participating institutions of YACHT. Among these 4362 patients, we retrospectively evaluated 14 adult patients with primary uterine lymphoma...
July 8, 2018: Asia-Pacific Journal of Clinical Oncology
Siavash Foroughi, Hui-Li Wong, Lucy Gately, Margaret Lee, Koen Simons, Jeanne Tie, Antony Wilks Burgess, Peter Gibbs
Substantial progress has recently been made in optimizing the management of cancer patients, resulting in major gains in survival and quality of life. Much of this progress has resulted from the serial testing of promising treatment strategies, typically using prospective randomized controlled trials to compare outcomes achieved with the new approach versus the current standard(s) of care. However, there is an ever-expanding list of important questions that are difficult to investigate, particularly with respect to determining the optimal sequencing and combination of proven active agents...
June 26, 2018: Asia-Pacific Journal of Clinical Oncology
Jiaxiong Tan, Shaohua Chen, Jingying Huang, Youchun Chen, Lijian Yang, Chunli Wang, Jun Zhong, Yuhong Lu, Liang Wang, Kanger Zhu, Yangqiu Li
AIM: The immunosuppressive microenvironment plays a crucial role in T-cell immunodeficiency in multiple myeloma (MM). Overexpression of T-cell immunosuppressive receptors, including programmed death-1 (PD-1) and T-cell immunoglobulin and mucin-domain-containing-3 (Tim-3), may be related to tumor immunosuppression and poor prognosis, and the malignant bone marrow (BM) microenvironment may contribute to such immunosuppression. The purpose of this study was to analyze the distribution of PD-1+ and/or Tim-3+ T cells in different T-cell subset in patients with MM...
June 25, 2018: Asia-Pacific Journal of Clinical Oncology
Rahul Ladwa, Victoria Atkinson
AIM: Improved systemic treatment has improved the prognosis of metastatic melanoma (MM). However, brain metastases (BMs) are a frequent complication. We aimed to explore the outcome of these patients with modern therapeutic options. METHOD: We retrospectively analyzed 142 patients diagnosed with BM from MM at two institutions in Brisbane, Queensland, Australia during 2009-2016. Basic clinico-pathological parameters, treatments used and mortality data were collected...
June 22, 2018: Asia-Pacific Journal of Clinical Oncology
Akira Hirano, Hiroaki Inoue, Kaoru Ogura, Akinori Hattori, Hiroko Yukawa, Shiho Sakaguchi, Aya Matsuoka, Natsuko Tanaka, Asaka Kodera, Mari Kamimura, Yoshihiko Naritaka, Tadao Shimizu
PURPOSE: Unlike anastrozole, the effect of long-term exemestane (EXE) therapy on bone mineral density (BMD) is still unknown. We assessed changes in BMD from baseline to 5 years of EXE treatment. METHODS: Postmenopausal women with endocrine-responsive breast cancer receiving EXE as adjuvant therapy were enrolled in this study. EXE was administered for 5 years. The BMD of the lumbar spine (LS) and femoral neck (FN) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 months and 1, 2, 3, 4, 5 and 6 years...
June 22, 2018: Asia-Pacific Journal of Clinical Oncology
Sally L Brooks, Gail Rowan, Michael Michael
AIM: Complementary medicine (CAM) use in the cancer population is higher than the general population: some studies estimate up to 70%. Our Medicines Information Centre, in a tertiary cancer institution, receives many enquiries regarding use and safety of CAM with conventional cancer therapies (chemotherapy, radiotherapy and surgery). This project aims to review the CAM most commonly enquired about with an emphasis on potential interactions with conventional cancer therapies. METHODS: An audit and review of CAM enquiries from patients or medical professionals at our center, over a 2-year period (July 2011-June 2013), was conducted...
June 22, 2018: Asia-Pacific Journal of Clinical Oncology
Yuwei Yang, MengMeng Zhou, Mingjun Hu, Yanjie Cui, Qi Zhong, Ling Liang, Fen Huang
BACKGROUND: Previous articles explored the role of UGT1A1 polymorphism on predicting irinotecan-induced toxicity, but the conclusions were still inconsistent and not comprehensive. We performed this meta-analysis to investigate the association between UGT1A1 polymorphism and irinotecan-induced toxicity. METHODS: PubMed and Web of Science were searched for articles before July 2017. Inclusion and exclusion criteria were set to select eligible articles, and corresponding data were extracted from those articles...
June 22, 2018: Asia-Pacific Journal of Clinical Oncology
Rosemary Young, Paul Mainwaring, Philip Clingan, Francis Xavier Parnis, Gholamreza Asghari, Philip Beale, Abdalla Aly, Marc Botteman, Alfredo Romano, Stefano Ferrara, Sandra Margunato-Debay, Marion Harris
AIM: The phase III MPACT trial (N = 861) demonstrated superior overall survival (OS) with first-line nab-paclitaxel plus gemcitabine versus gemcitabine alone (median, 8.7 months vs 6.6 months; hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.62-0.83; P < 0.001) in patients with metastatic pancreatic cancer. The efficacy benefit of the combination over gemcitabine alone was observed across patient subgroups, including those based on region. This subset analysis was designed to examine the safety and efficacy of nab-paclitaxel plus gemcitabine in patients treated in Australia to understand whether differences in patient population or regional variations in patient care had any impact on clinical outcomes...
June 22, 2018: Asia-Pacific Journal of Clinical Oncology
James C H Chow, Kwok Hung Au, Oscar W K Mang, Ka Man Cheung, Roger K C Ngan
AIM: Second primary tumor (SPT) is a serious late complication after definitive radiotherapy for nasopharyngeal carcinoma (NPC). We evaluated the incidence, pattern, risk factors and survival impact of SPT in NPC patients following definitive intensity-modulated radiotherapy (IMRT). METHODS: A retrospective review of 780 consecutive IMRT-treated NPC patients between February 2003 and September 2011 was conducted. Cumulative SPT incidence and overall survival after SPT diagnosis were estimated...
June 22, 2018: Asia-Pacific Journal of Clinical Oncology
Ivy Weishan Ng, Yu Yang Soon, Desiree Chen, Jeremy Chee Seong Tey
PURPOSE: To determine the benefit of adding radiotherapy (RT) to chemotherapy for patients with locally advanced unresectable pancreatic cancer (LAUPC). METHODS: We searched MEDLINE for comparative studies comparing chemoradiotherapy with chemotherapy for patients with LAUPC. We performed the meta-analysis with random effects model. The primary outcome was overall survival (OS); secondary outcomes include progression-free survival (PFS) and adverse events (AE). RESULTS: We found five randomized (RCT) and three observational studies (OBS) including 830 patients...
June 22, 2018: Asia-Pacific Journal of Clinical Oncology
Luigi A Sposato, Yick Lam, Chris Karapetis, Sina Vatandoust, Amitesh Roy, Paul Hakendorf, Andrew Dwyer, Dayan de Fontgalland, Paul Hollington, David Wattchow
AIM: Observation with close follow-up ("watch and wait") is a recognized treatment option in patients who achieve a complete clinical response to long course chemoradiotherapy. This review of a prospective database aims to evaluate the clinical outcomes among patients with a complete clinical response managed with observation. METHODS: A prospective study of 32 patients who achieved a complete clinical response was undertaken. The primary outcomes measured were overall and recurrence-free survival, and rate of organ preservation in patients who deferred immediate surgery...
June 22, 2018: Asia-Pacific Journal of Clinical Oncology
Yan Mi, Yinlong Zhao, Fang Shi, Mengmeng Zhang, Chunpeng Wang, Xin Liu
AIM: Urine cytokeratin 20 (CK20) has been reported as a novel diagnostic biomarker for bladder cancer (BC). This meta-analysis aims to evaluate the diagnostic value of urine CK20 for BC. METHODS: A systematic search for literatures was performed till March 31, 2018. Sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and the area under the summary receiver operator characteristic curve (AUC) were analyzed...
June 22, 2018: Asia-Pacific Journal of Clinical Oncology
Chan Ho Lee, Ja Yoon Ku, Won Young Park, Nam Kyung Lee, Hong Koo Ha
AIMS: To assess the accuracy of multiparametric magnetic resonance imaging (mpMRI), used in conjunction with the Prostrate Imaging Reporting and Data System (PI-RADS), version 2, in the detection of prostate cancer (PCa), and to determine the extent of the efficacy of mpMRI as a screening test in biopsy-naïve patients. METHODS: Retrospective analysis was conducted in 107 patients who underwent mpMRI prior to radical prostatectomy (RP) at a single institution. The mpMRI findings were reassessed using PI-RADS, version 2...
June 19, 2018: Asia-Pacific Journal of Clinical Oncology
Hwee Leong Tan, Claramae Shulyn Chia, Grace Hwei Ching Tan, Su Pin Choo, David Wai-Meng Tai, Clarinda Wei Ling Chua, Matthew Chau Hsien Ng, Khee Chee Soo, Melissa Ching Ching Teo
BACKGROUND: Metastatic gastric cancer has a poor prognosis. We aim to study how clinical features and prognosis differs between different metastatic sites, and to identify prognostic factors for overall survival. METHODS: We retrospectively reviewed patients with metastatic gastric adenocarcinoma managed at a tertiary referral cancer center over a 5-year period. We divided our cohort into three groups based on the site(s) of metastasis at presentation-peritoneal metastasis only (P), distant metastasis only (D), and peritoneal and distant metastases (PD)...
June 19, 2018: Asia-Pacific Journal of Clinical Oncology
Monique Batten, Bella Nguyen, Brandon Burke, Hilman Harryanto, Imogen Mitchell, Alison Davis
AIM: To examine the current patterns of end-of-life care of medical oncology patients dying in an Australian tertiary acute hospital setting in order to determine potential areas for improvement. METHODS: A retrospective observational study was undertaken of 295 consecutive adult medical oncology inpatients dying between 2010 and 2015. Charts were reviewed for evidence of (1) resuscitation plans, (2) acute interventions in the 48-h period prior to death, (3) palliative care involvement and (4) recognition of the dying patient and comfort care plans...
June 13, 2018: Asia-Pacific Journal of Clinical Oncology
Pei-Wei Huang, Wen-Chi Chou, Wen-Chi Shen, Chia-Yen Hung, Kuan-Gen Huang, Yu-Li Su, Chang-Hsien Lu, Chien-Ting Liu, Yueh-Shih Chang, Chi-Ting Liau
AIM: Pazopanib is a multitargeted tyrosine kinase inhibitor used as a standard treatment for chemotherapy-refractory recurrent or metastatic soft tissue sarcoma. This study aimed to evaluate the efficacy and safety of pazopanib for treatment of metastatic soft tissue sarcoma in the Asian population. METHODS: Fifty patients with chemotherapy-refractory recurrent or metastatic soft tissue sarcoma, who had received pazopanib treatment between 2015 and 2016 were enrolled...
June 13, 2018: Asia-Pacific Journal of Clinical Oncology
Hidekazu Hirano, Narikazu Boku
A multimodality approach plays a key role in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Currently, definitive chemoradiotherapy (dCRT) using 5-fluorouracil (5-FU) plus cisplatin with radiotherapy is the standard treatment in this population. dCRT regimens using 5-FU plus leucovorin plus oxaliplatin (FOLFOX), and carboplatin plus paclitaxel have been investigated in prospective clinical trials. Anti-epidermal growth factor receptor (EGFR) antibody has been evaluated in combination with dCRT; however, this combination has not revealed any additive benefits...
June 5, 2018: Asia-Pacific Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"